Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.
about
Antiplatelet resistance in strokeImpact of proton pump inhibitors on efficacy of clopidogrel: Review of evidenceClopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designsOverutilization of proton-pump inhibitors: what the clinician needs to knowThe drug-drug interaction between proton pump inhibitors and clopidogrelP2Y12-ADP receptor antagonists: Days of future and pastPersonalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfallsPharmacodynamic impacts of proton pump inhibitors on the efficacy of clopidogrel in vivo--a systematic reviewClopidogrel and proton pump inhibitors--where do we stand in 2012?Current perspectives in NSAID-induced gastropathyPharmacogenetics and anaesthesia: the value of genetic profilingTreatment and prevention of gastrointestinal bleeding in patients receiving antiplatelet therapyProton pump inhibitors in prevention of low-dose aspirin-associated upper gastrointestinal injuriesPharmacokinetic drug-drug interaction and their implication in clinical managementA review of the mechanisms and effectiveness of dietary polyphenols in reducing oxidative stress and thrombotic riskFluoxetine- and norfluoxetine-mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4Potential savings of harmonising hospital and community formularies for chronic disease medications initiated in hospitalEffects of Clopidogrel and Proton Pump Inhibitors on Cardiovascular Events in Patients with Type 2 Diabetes Mellitus after Drug-Eluting Stent Implantation: A Nationwide Cohort StudyProton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General PopulationImpact of proton pump inhibitor therapy on the efficacy of clopidogrel in the CAPRIE and CREDO trials.Clopidogrel: the data, the experience, and the controversies.Point-of-care platelet reactivity determination with VerifyNow-P2Y12 following administration of clopidogrel or prasugrel: data from a real-world, clinical care inpatient setting.Frequency of heparin/platelet factor 4-dependent platelet antibodies in patients undergoing angioplasty and stenting for cardiovascular disease and their role for on-clopidogrel platelet reactivity.Dexlansoprazole in the treatment of esophagitis and gastroesophageal reflux disease.Oral antiplatelet therapy for acute and chronic management of NSTE ACS: residual ischemic risk and opportunities for improvement.Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndromeClopidogrel and proton pump inhibitors: a new drug interaction?The impact of smoking on post-clopidogrel platelet reactivity in patients with acute myocardial infarction.The potential interaction between clopidogrel and proton pump inhibitors: a systematic review.The impact of treatment with omeprazole on the effectiveness of clopidogrel drug therapy during the first year after successful coronary stentingPantoprazole Does Not Reduce the Antiplatelet Effect of Clopidogrel: A Randomized Controlled Trial in KoreaAntiplatelet drug interactions with proton pump inhibitorsProton pump inhibitors and risk of vitamin and mineral deficiency: evidence and clinical implicationsImplementing genotype-guided antithrombotic therapy.Combined influence of proton-pump inhibitors, calcium-channel blockers and CYP2C19*2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention.Multivariate-adjusted pharmacoepidemiologic analyses of confidential information pooled from multiple health care utilization databasesPrivacy-maintaining propensity score-based pooling of multiple databases applied to a study of biologics.'Ins' and 'outs' of triple therapy: Optimal antiplatelet therapy in patients on chronic oral anticoagulation who need coronary stenting.Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypesEffects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro.
P2860
Q22305927-841404F0-2515-4EA0-B60D-D0BF9233B16BQ24608981-09810224-5B8E-4389-91B6-BD23D3A744A7Q24633087-E6171F8C-6D59-4265-B64C-4F2EE96FA841Q24634086-B6E8E855-E008-4127-A786-5DA23E24B5CCQ24653812-9E17D211-970A-4F9C-B750-19FE2CC47458Q26745619-E124B0F0-3261-4E1F-BC5C-D698BDFBBC9BQ26775125-C7804F57-505D-4016-AA07-EEFC95D5D141Q26822474-2A17AC55-A8BE-459C-A79D-FCF245CAA72CQ26825728-1DF38E8F-9254-411F-BCF6-82AEF1ED8265Q26827673-C45FC046-28F6-417C-B99F-FE27705DD4B6Q26859221-0AD10583-BD98-466E-A6BA-5ED71CE18E8FQ26866350-98777D92-9468-4E77-B8FE-1E6349E6125CQ27004834-CA99BAA4-E545-43B8-B2E0-50066B377382Q27021051-B39852AE-BBBC-4EC6-9245-A03FF5E2FE98Q28301541-62D0FA4A-7EED-42A2-B3CA-DD3CD1D13F03Q28307990-FEEE5FE5-9A2C-45D3-8535-8A32C9CB8157Q28480623-4D2B6A62-DE45-4F25-A570-0770C45D3D59Q28547539-4B8A8FB8-0F0A-4306-A097-7F2D6BA3B0ECQ28548045-92ED5D69-F2B4-47BF-967B-FDF023C67A2BQ30421742-EBA0ECAF-9020-4055-AA12-E2068AF31C62Q30573045-C782B690-CA59-4FE9-934D-9233190D4AA1Q30877943-4B02A298-1E64-4D0E-ACB1-4CF8A2D0B680Q33399119-B74ED4C7-CF98-4196-875D-9A439441DD74Q33445961-5393979F-9CF0-451F-9FA5-459F69D9F9FEQ33554381-FB24D2C6-5900-4D86-AB4A-4BE0937ECBF1Q33639452-A7021A94-1301-4542-A631-F7174D8B6420Q33705305-E81B46F5-D3E3-4E1F-9E5B-8DBB3ED70929Q33751281-CB0535CE-2DF0-4C1B-96B0-4443BC737E99Q33763929-DC4398A4-239F-4BF9-B2B1-26AF053AC44CQ33776115-70B3481A-7C6E-4E06-ACBF-859FBD9C0B9AQ33853179-5BC3BD55-8CB7-42D8-9E40-2D26CF3E1769Q33948811-2FE0EB62-678C-4D90-8CE7-4CF0BCD61BE2Q33949498-F57DC753-E69C-4668-8CC7-F7BEFBB49DCCQ33990428-8714D85F-A4CB-4981-A8D3-8BA97D416308Q33997642-7EA12737-4A01-48C4-A027-42A743FD9F78Q34039973-C2E1FA5D-41F1-4C6D-A737-B2A1060AB33CQ34104550-3178EE8B-B3D6-49C0-BFC4-08FA05954258Q34135274-E58F5549-69EE-4DEB-8888-6A7199BFFDA2Q34174915-67C28075-14DA-4B74-8E72-5F82B1580F0BQ34339780-5F18BF1C-A263-470A-B2D6-471BD512615D
P2860
Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Influence of omeprazole on the ...... le CLopidogrel Aspirin) study.
@ast
Influence of omeprazole on the ...... le CLopidogrel Aspirin) study.
@en
Influence of omeprazole on the ...... le CLopidogrel Aspirin) study.
@nl
type
label
Influence of omeprazole on the ...... le CLopidogrel Aspirin) study.
@ast
Influence of omeprazole on the ...... le CLopidogrel Aspirin) study.
@en
Influence of omeprazole on the ...... le CLopidogrel Aspirin) study.
@nl
prefLabel
Influence of omeprazole on the ...... le CLopidogrel Aspirin) study.
@ast
Influence of omeprazole on the ...... le CLopidogrel Aspirin) study.
@en
Influence of omeprazole on the ...... le CLopidogrel Aspirin) study.
@nl
P2093
P1476
Influence of omeprazole on the ...... le CLopidogrel Aspirin) study.
@en
P2093
Bertrand Arnaud
Dominique Mottier
Geneviève Le Calvez
Grégoire Le Gal
Jacques Boschat
Jacques Mansourati
Jean-Christophe Cornily
Jean-François Abgrall
Karine Lacut
Martine Gilard
P304
P356
10.1016/J.JACC.2007.06.064
P407
P577
2008-01-01T00:00:00Z